drugset / Trial / NCT03030261
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Phase 2
Active not recruiting
25 enrolled
Washington University School of Medicine
Bristol-Myers Squibb · collabCelgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate maintenance/continuation therapy following second ASCT. Pomalidomide is active against MM cells refractory to both bortezomib and lenalidomide, making it an ideal choice for continuation therapy following second ASCT. Adding elotuzumab may increase efficacy and also the durability of responses which is essential to improving outcomes following second ASCT.
Timeline
- Start
- 2017-11-22
- Primary completion
- 2022-09-29
- Completion
- 2027-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Elotuzumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |